Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study [0.03%]
评估地西他滨和/或venetoclax治疗加速期和急变期骨髓增殖性肿瘤患者的疗效：一项HERO联盟研究
Jenna Ciervo,Anthony J Perissinotti,Adam J DiPippo et al.
Jenna Ciervo et al.
Patients with accelerated-phase/blast-phase myeloproliferative neoplasms (AP/BP-MPN) experience poor clinical outcomes. A multicenter, retrospective cohort study was conducted to assess outcomes of patients with AP/BP-MPN treated with hypom...
Marcel von Lucadou,Lea-Corinna Burbaum,Melanie Märklin et al.
Marcel von Lucadou et al.
Soluble immune mediators, such as checkpoint and cytokine receptors and their ligands, are emerging as biomarkers and potential therapeutic targets in hematologic malignancies. We assessed pretreatment levels of soluble PD-L1 (sPD-L1) as a ...
Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia [0.03%]
单剂Inotuzumab Ozogamicin成人复发/难治性急性淋巴细胞白血病剂量优化研究
Daniel J DeAngelo,Ying Chen,Ryan D Cassaday et al.
Daniel J DeAngelo et al.
Following the approval of inotuzumab ozogamicin (InO) monotherapy for the treatment of adults with relapsed/refractory CD22-positive acute lymphoblastic leukemia, the US Food and Drug Administration issued a post-marketing requirement study...
Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study [0.03%]
基于维奈克拉方案的初治急性髓系白血病患者的社区剥夺指数对其预后的影响：单中心回顾性研究
Bradley Uyemura,Fauzia Hollnagel,Aric Hall et al.
Bradley Uyemura et al.
Biological markers such as disease risk and mutation profile can predict survival outcomes of acute myeloid leukemia (AML) treated with first-line venetoclax (Ven) in combination with a hypomethylating agent. However, the impact of socioeco...
Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies [0.03%]
CAR-T和新型免疫疗法时代的复发或难治性弥漫性大B细胞淋巴瘤患者的姑息治疗和临终关怀利用情况
Danny Trotier,Manlu Liu,Arun Augustine et al.
Danny Trotier et al.
Chimeric antigen receptor T-cell therapy (CART) has changed treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but most patients still die of their disease and may benefit from palliative care (PC) or hospice servi...
How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature [0.03%]
浆细胞瘤肝髓外浸润的治疗：1例报告及文献复习
Ece Vural,Hamit Aytekin,Emine Durak et al.
Ece Vural et al.
Extramedullary hepatic involvement is particularly rare. Here, we summarize published reports of hepatic myeloma treatment achieving infrequent and short-lived responses. Approach to a newly diagnosed multiple myeloma patient who presented ...
Additional myelodysplasia-related gene mutations alter clinical presentation and worsen prognosis in patients with SRSF/ TET2 co-mutated myeloid neoplasms [0.03%]
额外的骨髓增生异常相关基因突变可改变SRSF/TET2共突变性髓系肿瘤患者的临床表现并恶化预后
Michael Martin,Samuel G Cockey,Veena Jajoo et al.
Michael Martin et al.
SRSF2/TET2 is a common co-mutation characterized by monocytosis across many myeloid neoplasms, including CMML. Myelodysplasia-related gene (MRG) mutations, including SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, are key contribu...
Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma [0.03%]
靶向T细胞衔接剂在多发性骨髓瘤中相关感染的特征及预后意义
Lindsay Fogel,Harsh Parmar,Shucen Wan et al.
Lindsay Fogel et al.
Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group [0.03%]
Venetoclax联合利妥昔单抗治疗复发/难治慢性淋巴细胞白血病的疗效和耐受性——波兰成人急性白血病研究组真实世界分析
Anita Soboń,Elżbieta Iskierka-Jażdżewska,Joanna Drozd-Sokolowska et al.
Anita Soboń et al.
We collected clinical data on 363 patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL) treated with venetoclax-rituximab (VR) in a real-world setting. The median age was 69.5 years (range, 32.5-91.6 years), and the median...